RxDoctor Payments Data

Chanaka Wickramasinghe, MD

Cardiovascular Disease · Rancho Mirage, CANPI 1174840680

Payments from drug & device makers

$24,822in general payments, 2019–2025

Across 159 payments — averaging $156.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endotronix, Inc.$19K
  • Abbott$3K
  • Boston Scientific$1K
  • Bard Peripheral Vascular, Inc.$773
  • Acutus Medical, Inc.$286
  • Johnson & Johnson$167
  • plus $629 from 9 others

What the payments were for

  • Travel & lodging$1,39224%
  • Food & beverage$4,48076%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,822 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$725,435
Medicare patients
2,806
Services billed
17,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban401$512,612
XareltoRivaroxaban207$252,655
JardianceEmpagliflozin158$194,383
Repatha SureclickEvolocumab104$144,032
EntrestoSacubitril/Valsartan52$68,926
MultaqDronedarone Hcl34$61,842
Praluent PenAlirocumab29$29,200
Rosuvastatin Calcium843$16,370
BrilintaTicagrelor21$14,369
VascepaIcosapent Ethyl23$12,913
Dabigatran EtexilateDabigatran Etexilate Mesylate27$10,344
Flecainide Acetate134$7,882
Diltiazem 24hr Er (Cd)Diltiazem Hcl188$7,576
Atorvastatin Calcium585$6,843
Clonidine43$6,707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$167$252,655207 claims
NovartisEntresto$61$68,92652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →